Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic
  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Context Therapeutics shares #ASCO23 data on CLDN-6 targeted treatments and CTIM-76 update

Context Therapeutics CEO Marty Lehr joins Natalie Stoberman from the Proactive studios to discuss the latest data on clinical cancer target Claudin 6 (CLDN6) presented at ASCO23 and how Context’s CTIM-76 CLDN6 X CD3 bispecific antibody sets itself apart from other CLDN6-targeted clinical candidates.

Lehr says CLDN6 is differentially expressed on cancer cells with no or very low expression in normal, healthy adult tissue. CLDN6-enriched cancers include non-small cell lung (NSCLC), ovarian, testicular, and others.

CTIM-76 is currently in preclinical development and is intended to direct activated immune T cells to CLDN6-expressing cancer cells. Preclinical studies of evaluating CTIM-76 demonstrates selective immune-mediated cell death of CLDN6-positive cancer cells.

Contact Details

Proactive Investors USA

+1 347-449-0879

na-editorial@proactiveinvestors.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.